Overall, these results suggest that ω-3 vs. ω-6 metabolites produced by the CYP enzymes have opposite effects on CRC, supporting the hypothesis that the CYP pathway could contribute to the anti-CRC effects of ω-3 PUFAs. The gene discussed is PPIG; the disease is colorectal carcinoma.